Loading…
Scholar Rock Holding Corporation is projected to rise to $66.02 by 2027, a +35% move from its current price of $48.99. SRRK is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $47.93 | $49.01 | $50.13 | +0.05% |
| Aug 2 | $47.51 | $49.04 | $50.62 | +0.10% |
| Aug 3 | $47.19 | $49.06 | $51.01 | +0.15% |
| Aug 4 | $46.93 | $49.09 | $51.34 | +0.20% |
| Aug 5 | $46.71 | $49.11 | $51.64 | +0.25% |
| Aug 6 | $46.51 | $49.14 | $51.92 | +0.30% |
| Aug 7 | $46.33 | $49.16 | $52.17 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $46.33 | $49.16 | $52.17 | +0.36% |
| Week 2 | $45.36 | $49.34 | $53.66 | +0.71% |
| Week 3 | $44.67 | $49.51 | $54.88 | +1.07% |
| Week 4 | $44.13 | $49.69 | $55.96 | +1.43% |
| Week 5 | $43.67 | $49.87 | $56.95 | +1.79% |
| Week 6 | $43.27 | $50.04 | $57.88 | +2.15% |
| Week 7 | $42.92 | $50.22 | $58.77 | +2.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Scholar Rock Holding Corporation is a healthcare biopharmaceutical company focused on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company uses a proprietary platform built around the activation of growth factors within the transforming growth factor beta (TGFß) superfamily to develop monoclonal antibodies that target precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, in a Phase 2 clinical trial for SMA and facioscapulohumeral muscular dystrophy (FSHD).
Additionally, SRK-439 is in Phase 1, SRK-181 is a Phase 2-ready inhibitor of latent TGFß1, and there are pre-clinical programs including SRK-373 and SRK-256. Scholar Rock was founded in 2012 and is headquartered in Cambridge, Massachusetts.
The described pipeline and research focus illustrate Scholar Rock’s emphasis on neuromuscular and related diseases through a platform aimed at latent growth factor activity, with multiple programs at various clinical stages.
Scholar Rock Holding Corporation (SRRK) is a healthcare stock with a current price of $47.67 and a market capitalization of $5.71B, ranking 1187. This positions the company within a broad biotechnology and healthcare market segment.
Technically, the stock trades relative to key moving averages, with the 50-day moving average at $50.06 and the 200-day moving average at $44.39. The near-term price landscape includes a 30-day range from $40.63 to $55.93, with a near-term support at $44.09 and resistance at $57.94.
Looking further out, the forecast shows a bullish long-term path, with multi-year averages projecting meaningful upside: 2027 avg $67.76 and 2030 avg $103.17, rising to 2050 avg $678.14 with a max around $1,200.65. These projections imply substantial potential upside over extended horizons.
A major floor 17.7% below — a decisive break under it would weaken the trend.
The nearest floor, 4.2% below — buyers have tended to step in here.
The nearest ceiling, 18.3% above — a clean break opens room to run.
A major ceiling 27.1% above — clearing it would confirm fresh momentum.
Key SRRK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SRRK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $48.80 | Buy | $49.15 | Sell |
| MA 10 | $49.62 | Sell | $49.88 | Sell |
| MA 20 | $52.40 | Sell | $50.76 | Sell |
| MA 50 | $49.99 | Sell | $50.27 | Sell |
| MA 100 | $48.31 | Buy | $48.59 | Buy |
| MA 200 | $44.62 | Buy | $45.26 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.58 | Neutral |
| Stoch RSI (14) | 23.91 | Neutral |
| CCI (20) | -78.59 | Neutral |
| Williams %R (14) | -81.22 | Info |
| MACD (12,26,9) | -0.64 | Sell |
| ROC (12) | -8.91 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 18.78 | Buy |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | -2.57 | Sell |
| Ultimate (7,14,28) | 36.69 | Neutral |
| Momentum (10) | -2.74 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 48.92 | Buy |
| ADX (14) | 17.90 | Neutral |
| ATR (14) | 1.10 | Info |
In the near term, the technical tone is described as BULLISH, with the RSI(14) at 40 and price action contained within a defined 30-day window. The stock sits above the 200-day moving average, which is $44.39, and sits near the 50-day moving average of $50.06, reflecting modest positive momentum.
Support is identified at $44.09 while resistance is at $57.94, guiding near-term price dynamics. The 30-day range extends from $40.63 to $55.93, providing a framework for short-term movement within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $39.79 | $48.99 | $68.08 | 0% | Neutral | |
| $53.50 | $66.02 | $85.59 | +35% | Bullish | |
| $62.29 | $78.64 | $105.23 | +61% | Bullish | |
| $71.50 | $91.98 | $126.16 | +88% | Bullish | |
| $73.19 | $95.71 | $134.04 | +95% | Bullish | |
| $79.51 | $105.53 | $150.52 | +115% | Bullish | |
| $86.81 | $116.81 | $169.37 | +138% | Bullish | |
| $96.61 | $131.68 | $193.79 | +169% | Bullish | |
| $120.46 | $166.21 | $247.99 | +239% | Bullish | |
| $127.63 | $178.15 | $269.21 | +264% | Bullish | |
| $182.36 | $268.21 | $427.65 | +447% | Bullish | |
| $337.24 | $541.62 | $934.50 | +10.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $39.79 | $48.99 | $57.15 | +0.00% |
| August 2026 | $43.61 | $50.99 | $60.87 | +4.08% |
| September 2026 | $43.58 | $51.31 | $61.93 | +0.63% |
| October 2026 | $44.23 | $52.36 | $63.76 | +2.05% |
| November 2026 | $45.90 | $54.57 | $66.93 | +4.23% |
| December 2026 | $46.20 | $55.16 | $68.08 | +1.07% |
Click any year to see its month-by-month SRRK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SRRK is projected to trade between $39.79 and $68.08, averaging $48.99 — a potential gain of 0% from today's $48.99. A consolidation phase looks the most probable path here.
Scholar Rock Holding Corporation's 2027 outlook centres on $66.02, within a $53.50 to $85.59 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2028, SRRK could reach as high as $105.23, with a base case around $78.64 and support toward $62.29 — roughly +61% from $48.99. Buyers look set to stay in control over this stretch.
Expect SRRK to range from $71.50 to $126.16 through 2029. The $91.98 average target implies a +88% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The SRRK price prediction for 2030 points to an average of $95.71 (low $73.19, high $134.04) — a potential gain of +95% on today's $48.99. Buyers look set to stay in control over this stretch.
In 2031, SRRK is projected to trade between $79.51 and $150.52, averaging $105.53 — a potential gain of +115% from today's $48.99. That is up +10% on the projected 2030 average. Momentum favours further upside here.
Scholar Rock Holding Corporation's 2032 outlook centres on $116.81, within a $86.81 to $169.37 range. That is up +11% on the projected 2031 average. That marks a +138% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SRRK could reach as high as $193.79, with a base case around $131.68 and support toward $96.61 — roughly +169% from $48.99. Momentum favours further upside here.
Expect SRRK to range from $120.46 to $247.99 through 2034. The $166.21 average target implies a +239% move from current prices. That is up +26% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SRRK price prediction for 2035 points to an average of $178.15 (low $127.63, high $269.21) — a potential gain of +264% on today's $48.99. Momentum favours further upside here.
In 2040, SRRK is projected to trade between $182.36 and $427.65, averaging $268.21 — a potential gain of +447% from today's $48.99. That is up +51% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Scholar Rock Holding Corporation's 2050 outlook centres on $541.62, within a $337.24 to $934.50 range. That is up +102% on the projected 2040 average. That marks a +10.1x change versus current levels. Momentum favours further upside here.
Investing $1,000 in SRRK today (≈ 20.412329 SRRK) could be worth
$11,055.78
+$10,055.78 (+1006%) by 2050 · US Dollar
Based on the average projected SRRK price of $541.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SRRKwould be worth at today's price.
$1,000 invested in SRRK on Jul 30, 2025 (≈ 26.434046 SRRK) would be worth
$1,295
+$295 (+29.5%) today · 1.30× · US Dollar
Based on a SRRK entry price of $37.83 vs. today's $48.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $49.48 | $990.1 | -1.0% |
| 1 month ago | $55 | $890.73 | -10.9% |
| 3 months ago | $46.37 | $1,056.5 | +5.7% |
| 6 months ago | $44.34 | $1,104.87 | +10.5% |
| 1 year ago | $37.83 | $1,295 | +29.5% |
| All time (5.0y) ago | $34.34 | $1,426.62 | +42.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SRRK forecast.
Our base-case forecast reaches $98.00 around 2031.
Implied market cap at $98.00: $11.74B
The multi-year forecast portrays a clear upward trajectory starting from 2026, where the min is $39.79, the avg is $47.67, and the max is $67.82 (ROI 0; sentiment Neutral). By 2027, the avg rises to $67.76 with a max of $88.63 and ROI of 42.1% (Bullish). In 2028, the avg is $82.35, the max $111.40, ROI 72.7% (Bullish); 2029 shows avg $97.57, max $135.53, ROI 104.7% (Bullish); and 2030 forecasts an avg of $103.17, max $146.52, ROI 116.4% (Bullish).
The forecast continues higher with 2031 avg $115.67, 2032 avg $130.11, and 2033 avg $151.35, with corresponding maxes and rising ROI (e.g., 2033 ROI 217.5%). By 2034, the avg is $193.82 and by 2035 it is $206.91, both with strong upside potential (ROI 306.6% and 334.1%, respectively). The long-range view extends to 2040 with avg $331.96 and max $540.85 (ROI 596.4%), and to 2050 with avg $678.14 and max $1,200.65 (ROI 1322.6%).
Across these years, the sentiment remains BULLISH, illustrating an expansive long-term outlook, though these figures are forecasts and not guarantees.
Tap a question to reveal the answer.
The forecast shows an avg price of $103.17, with a min of $78.02 and a max of $146.52; the ROI is projected at 116.4% in 2030, with bullish sentiment.
Forecasts indicate a bullish long-term path with rising averages and higher ROI over time, but these are estimates, not guarantees, and should be considered in the context of risk.
Yes. The 2033 forecast lists an avg of $151.35 and a max of $226.55, suggesting that hitting or exceeding $150 is plausible within the 2033 horizon.
Current price is $47.67 and market cap is $5.71B.
RSI(14) = 40; SMA50 = $50.06; SMA200 = $44.39; 30-day range = $40.63–$55.93; support = $44.09; resistance = $57.94.
Scholar Rock Holding Corporation Community Discussion
0Share your Scholar Rock Holding Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.